Tolterodine in the Treatment of Male LUTS.

about

Tolterodine in the Treatment of Male LUTS.

Item

http://www.wikidata.org/entity/Q38543432

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Tolterodine in the Treatment of Male LUTS.

@en

type

Item

label

Tolterodine in the Treatment of Male LUTS.

@en

prefLabel

Tolterodine in the Treatment of Male LUTS.

@en

P1476

Tolterodine in the Treatment of Male LUTS

@en

P2093

Andrea Tubaro

http://www.w3.org/2001/XMLSchema#string

Arcangelo Sebastianelli

http://www.w3.org/2001/XMLSchema#string

Eugenio Brunocilla

http://www.w3.org/2001/XMLSchema#string

Giacomo Novara

http://www.w3.org/2001/XMLSchema#string

Marco Carini

http://www.w3.org/2001/XMLSchema#string

Matthias Oelke

http://www.w3.org/2001/XMLSchema#string

Mauro Gacci

http://www.w3.org/2001/XMLSchema#string

Riccardo Schiavina

http://www.w3.org/2001/XMLSchema#string

Sergio Serni

http://www.w3.org/2001/XMLSchema#string

Stavros Gravas

http://www.w3.org/2001/XMLSchema#string

P2860

Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline

Tolterodine in the treatment of overactive bladder: analysis of the pooled phase II efficacy and safety data.

Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.

Tolterodine: a review of its use in the treatment of overactive bladder.

A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder.

Tolterodine extended-release for overactive bladder.

EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction.

The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society.

Persistence with antimuscarinic therapy in patients with overactive bladder.

Established medical therapy for benign prostatic hyperplasia.

P2888

s11934-015-0531-9

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11934-015-0531-9

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Cosimo De Nunzio

Mario Salvi

P577

2015-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1042400165

http://www.w3.org/2001/XMLSchema#string

P698

26149965

http://www.w3.org/2001/XMLSchema#string